3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Breast Neoplasms
5
Neoplasms
3
Polycystic Ovary Syndrome
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Insulin Resistance
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Drug-drug Interaction,SHR3680
1
Diabetes Mellitus, Type 2
1
Colonic Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Advanced Solid Malignancies
1
Interventions
relacorilant
5
somapacitan
1
semaglutide
1
saxagliptin
1
pembrolizumab
1
empagliflozin
1
dapagliflozin
1
Rosiglitazone
1
Metformin
1
Dipeptidyl-Peptidase IV Inhibitors
1
ASP3662
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diabetes Mellitus, Type 2
×
Metformin
×
Clear all
NCT01195259
2013-10-28
Malignancy Meta Analysis for BRL49653
GlaxoSmithKline
Completed
1 enrolled